Charles River Laboratories International Capital Expenditures (CapEx) Growth & History (CRL)
Charles River Laboratories International's capital expenditures (capex) was $219.2M for fiscal 2025.
View full Charles River Laboratories International company overviewCharles River Laboratories International annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-27 | $219.2M | −$13.8M | −5.93% |
| 2024 | 2024-12-28 | $233.0M | −$85.6M | −26.86% |
| 2023 | 2023-12-30 | $318.5M | −$6.2M | −1.91% |
| 2022 | 2022-12-31 | $324.7M | $96.0M | +41.95% |
| 2021 | 2021-12-25 | $228.8M | $62.2M | +37.35% |
| 2020 | 2020-12-26 | $166.6M | $26.0M | +18.54% |
| 2019 | 2019-12-28 | $140.5M | $460,000 | +0.33% |
| 2018 | 2018-12-29 | $140.1M | $57.6M | +69.90% |
| 2017 | 2017-12-30 | $82.4M | $27.1M | +49.09% |
| 2016 | 2016-12-31 | $55.3M | −$8.0M | −12.59% |
| 2015 | 2015-12-26 | $63.3M | $6.3M | +11.11% |
| 2014 | 2014-12-27 | $56.9M | $17.8M | +45.39% |
| 2013 | 2013-12-28 | $39.2M | −$8.4M | −17.63% |
| 2012 | 2012-12-29 | $47.5M | −$1.6M | −3.27% |
| 2011 | 2011-12-31 | $49.1M | $6.3M | +14.66% |
| 2010 | 2010-12-25 | $42.9M | −$37.0M | −46.33% |
| 2009 | 2009-12-26 | $79.9M | −$118.8M | −59.80% |
| 2008 | 2008-12-27 | $198.6M | — | — |
Charles River Laboratories International quarterly capital expenditures (capex)
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-27 | $31.1M | −$4.2M | −11.88% |
| Q1 2026 | 2026-03-28 | $55.9M | −$3.4M | −5.76% |
| Q4 2025 | 2025-12-27 | $89.0M | $13.3M | +17.63% |
| Q3 2025 | 2025-09-27 | $35.6M | −$3.1M | −8.11% |
| Q2 2025 | 2025-06-28 | $35.3M | −$4.2M | −10.61% |
| Q1 2025 | 2025-03-29 | $59.3M | −$19.8M | −25.04% |
| Q4 2024 | 2024-12-28 | $75.6M | −$2.7M | −3.46% |
| Q3 2024 | 2024-09-28 | $38.7M | −$27.2M | −41.28% |
| Q2 2024 | 2024-06-29 | $39.5M | −$27.9M | −41.40% |
| Q1 2024 | 2024-03-30 | $79.1M | −$27.7M | −25.95% |
| Q4 2023 | 2023-12-30 | $78.3M | −$10.7M | −12.02% |
| Q3 2023 | 2023-09-30 | $65.9M | −$6.4M | −8.90% |
| Q2 2023 | 2023-07-01 | $67.4M | −$15.5M | −18.67% |
| Q1 2023 | 2023-04-01 | $106.9M | $26.4M | +32.82% |
| Q4 2022 | 2022-12-31 | $89.0M | −$9.8M | −9.87% |
| Q3 2022 | 2022-09-24 | $72.4M | $16.9M | +30.35% |
| Q2 2022 | 2022-06-25 | $82.9M | $36.4M | +78.44% |
| Q1 2022 | 2022-03-26 | $80.5M | $52.4M | +187.06% |
| Q4 2021 | 2021-12-25 | $98.8M | $10.9M | +12.43% |
| Q3 2021 | 2021-09-25 | $55.5M | $29.4M | +112.09% |
| Q2 2021 | 2021-06-26 | $46.4M | $19.6M | +73.25% |
| Q1 2021 | 2021-03-27 | $28.0M | $2.3M | +8.98% |
| Q4 2020 | 2020-12-26 | $87.9M | $24.0M | +37.62% |
| Q3 2020 | 2020-09-26 | $26.2M | −$9.0M | −25.53% |
| Q2 2020 | 2020-06-27 | $26.8M | $2.0M | +8.15% |
| Q1 2020 | 2020-03-28 | $25.7M | $9.0M | +53.73% |
| Q4 2019 | 2019-12-28 | $63.8M | −$4.8M | −7.04% |
| Q3 2019 | 2019-09-28 | $35.2M | $12.7M | +56.70% |
| Q2 2019 | 2019-06-29 | $24.8M | $3.6M | +16.82% |
| Q1 2019 | 2019-03-30 | $16.7M | −$11.0M | −39.66% |
| Q4 2018 | 2018-12-29 | $68.7M | $40.2M | +140.94% |
| Q3 2018 | 2018-09-29 | $22.4M | $428,000 | +1.94% |
| Q2 2018 | 2018-06-30 | $21.2M | $5.2M | +32.61% |
| Q1 2018 | 2018-03-31 | $27.7M | $11.8M | +74.16% |
| Q4 2017 | 2017-12-30 | $28.5M | $2.8M | +11.00% |
| Q3 2017 | 2017-09-30 | $22.0M | $12.4M | +130.05% |
| Q2 2017 | 2017-07-01 | $16.0M | $4.2M | +35.67% |
| Q1 2017 | 2017-04-01 | $15.9M | $7.7M | +92.97% |
| Q4 2016 | 2016-12-31 | $25.7M | −$2.6M | −9.08% |
| Q3 2016 | 2016-09-24 | $9.6M | −$884,000 | −8.46% |
| Q2 2016 | 2016-06-25 | $11.8M | −$2.1M | −15.22% |
| Q1 2016 | 2016-03-26 | $8.3M | −$2.4M | −22.52% |
| Q4 2015 | 2015-12-26 | $28.2M | $1.2M | +4.54% |
| Q3 2015 | 2015-09-26 | $10.5M | $1.1M | +11.17% |
| Q2 2015 | 2015-06-27 | $13.9M | $4.6M | +49.31% |
| Q1 2015 | 2015-03-28 | $10.6M | −$542,000 | −4.84% |
| Q4 2014 | 2014-12-27 | $27.0M | $13.2M | +95.29% |
| Q3 2014 | 2014-09-27 | $9.4M | $306,000 | +3.36% |
| Q2 2014 | 2014-06-28 | $9.3M | −$479,000 | −4.89% |
| Q1 2014 | 2014-03-29 | $11.2M | $4.8M | +74.06% |
| Q4 2013 | 2013-12-28 | $13.8M | $96,000 | +0.70% |
| Q3 2013 | 2013-09-28 | $9.1M | −$1.1M | −11.19% |
| Q2 2013 | 2013-06-29 | $9.8M | $353,000 | +3.74% |
| Q1 2013 | 2013-03-30 | $6.4M | −$7.7M | −54.44% |
| Q4 2012 | 2012-12-29 | $13.7M | −$13.7M | −49.99% |
| Q3 2012 | 2012-09-29 | $10.2M | $2.0M | +24.57% |
| Q2 2012 | 2012-06-30 | $9.4M | $2.8M | +41.74% |
| Q1 2012 | 2012-03-31 | $14.1M | $7.3M | +107.87% |
| Q4 2011 | 2011-12-31 | $27.5M | $11.5M | +71.62% |
| Q3 2011 | 2011-09-24 | $8.2M | −$906,000 | −9.93% |
| Q2 2011 | 2011-06-25 | $6.7M | −$1.8M | −21.00% |
| Q1 2011 | 2011-03-26 | $6.8M | −$2.5M | −26.95% |
| Q4 2010 | 2010-12-25 | $16.0M | — | — |
| Q3 2010 | 2010-09-25 | $9.1M | −$9.3M | −50.57% |
| Q2 2010 | 2010-06-26 | $8.4M | — | — |
| Q1 2010 | 2010-03-27 | $9.3M | — | — |
| Q3 2009 | 2009-09-26 | $18.5M | — | — |
Charles River Laboratories International capital expenditures (capex) trends
Over the last five fiscal years, Charles River Laboratories International's capital expenditures (capex) increased from $166.6M to $219.2M, a change of $52.6M. The latest reported quarter, Q2 2026, shows $31.1M.
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Charles River Laboratories International source filings ↗